Next Article in Journal
A Quick and Efficient Non-Targeted Screening Test for Saffron Authentication: Application of Chemometrics to Gas-Chromatographic Data
Previous Article in Journal
Coinage-Metal Bond between [1.1.1]Propellane and M2/MCl/MCH3 (M = Cu, Ag, and Au): Cooperativity and Substituents
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 24
Issue 14
10.3390/molecules24142603
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Design, Synthesis, and Biological Evaluation of EdAP, a 4′-Ethynyl-2′-Deoxyadenosine 5′-Monophosphate Analog, as a Potent Influenza a Inhibitor

by
Toshifumi Takeuchi
1,*,†,
Nongluk Sriwilaijaroen
2,3,†,
Ayako Sakuraba
1,
Ei Hayashi
1,
Shinji Kamisuki
4,
Yasuo Suzuki
3,
Hiroshi Ohrui
5 and
Fumio Sugawara
1
1
Department of Applied Biological Science, Faculty of Science and Technology, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan
2
Department of Preclinical Sciences, Faculty of Medicine, Thammasat University, Pathumthani 12120, Thailand
3
Health Science Hills, College of Life and Health Sciences, Chubu University, Kasugai, Aichi 487-8501, Japan
4
School of Veterinary Medicine, Azabu University, 1-17-71 Fuchinobe, Chuo-ku, Sagamihara, Kanagawa 252-5201, Japan
5
Yokohama University of Pharmacy, Matano-cho 601, Totsuka-ku, Yokohama, Kanagawa 245-0066, Japan
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Molecules 2019, 24(14), 2603; https://doi.org/10.3390/molecules24142603
Submission received: 20 June 2019 / Revised: 10 July 2019 / Accepted: 16 July 2019 / Published: 17 July 2019
(This article belongs to the Section Bioorganic Chemistry)
Browse Figures
Versions Notes

Abstract

:
Influenza A viruses leading to infectious respiratory diseases cause seasonal epidemics and sometimes periodic global pandemics. Viral polymerase is an attractive target in inhibiting viral replication, and 4′-ethynyladenosine, which has been reported as a highly potent anti-human immunodeficiency virus (HIV) nucleoside derivative, can work as an anti-influenza agent. Herein, we designed and synthesized a 4′-ethynyl-2′-deoxyadenosine 5′-monophosphate analog called EdAP (5). EdAP exhibited potent inhibition against influenza virus multiplication in Madin–Darby canine kidney (MDCK) cells transfected with human α2-6-sialyltransferase (SIAT1) cDNA and did not show any toxicity toward the cells. Surprisingly, this DNA-type nucleic acid analog (5) inhibited the multiplication of influenza A virus, although influenza virus is an RNA virus that does not generate DNA.

Graphical Abstract

1. Introduction

Influenza caused by influenza A virus is an infectious respiratory disease, which is responsible for seasonal epidemics and periodic global pandemics. This infection causes mild to severe illness, including death, in persons with an increased risk for severe diseases, including the elderly, infants, and the ill, resulting in three to five million severe cases and 250,000 to 500,000 deaths worldwide [1]. The most efficient prevention method in healthy adults is vaccination. However, for the elderly, vaccination may be less efficient and may increase complications and death. Four classes of antiviral medicines are currently available. These include (i) the neuraminidase inhibitors oseltamivir (Roche), zanamivir (GlaxoSmithKline), peramivir (BioCryst Pharmaceuticals), and laninamivir octanoate (Daiichi Sankyo); (ii) the M2 ion channel blockers rimantadine (Sun Pharma) and amantadine (Endo); (iii) favipiravir (Toyama Chemical), which inhibits the ribonucleic acid (RNA)-dependent RNA polymerase; and (iv) a cap-dependent endonuclease inhibitor, baloxariv marboxil (Shionogi) [2,3,4]. M2 ion channel blockers have been previously used to treat influenza. However, the virus resistance of this class of medicine has been frequently reported to limit treatment efficiency.
The influenza A virus is a negative-sense single-strand RNA virus with a lipid envelope. The viral genome is divided into eight segments that encode nine structural proteins and a variable number of nonstructural proteins depending on the virus strain and host species. Each segment is packaged in a complex together with an RNA-dependent RNA polymerase, composed of polymerase basic 1 (PB1), polymerase basic 2 (PB2) and polymerase acidic (PA) proteins, involved in viral RNA transcription and replication [2].
Each viral polymerase is an attractive target for developing a new antiviral compound. The inhibitors should work against several subtypes of influenza A viruses and be tolerated by a drug-resistant mutant because it is highly conserved in all influenza subtypes and is essential to the viral life cycle. We have previously reported on a highly potent antihuman immunodeficiency virus (HIV) nucleoside derivative called 4′-ethynyl-2-fluoro-2′-deoxyadenosine (EFdA, 1, Figure 1) [5,6,7,8,9,10,11,12,13]. EFdA is an adenosine derivative armed with an ethynyl group at the 4′-position, which prevents the extension of a nucleotide at 3′-OH because of its steric hindrance by the 4′-substituent, providing features of a viral DNA chain terminator and a reverse transcriptase inhibitor [14,15,16,17,18]. EFdA is currently used in human clinical trials [19,20,21,22,23,24]. Herein, we hypothesize that EFdA derivatives may work as an anti-influenza inhibitor. We subsequently describe the discovery of a new 4′-ethynyl-2′-deoxyadenosine 5′-monophosphate analog called EdAP (5) as a potent inhibitor of influenza A virus. Interestingly, this DNA-type nucleic acid analog inhibited the multiplication of influenza A virus, although influenza A virus is an RNA virus that does not generate DNA.

2. Results and Discussion

2.1. Effect of Compounds 1–3 on Anti-Influenza Activities

We intended to analyze the anti-influenza activity of 4′-ethynyl adenosine derivatives, namely EFdA (1), 4′-ethynyl-2′-deoxyadenosine (EdA, 2) [13], and 4′-ethynyl-2-fluoroadenosine (EA, 3), based on our hypothesis that EFdA analogs may work against the influenza virus [25]. The adenosine derivatives of compounds 1–3 were evaluated for their in vitro anti-influenza activities against the H1N1 virus using MDCK-SIAT1 according to a procedure that has been previously described [26]. The deoxynucleoside-type derivatives 1 and 2 displayed modest and weak activities, respectively, whereas the nucleoside-type derivative 3 did not show any activity (Table 1). The cytotoxicity of compounds 1–3 was also determined using a cell counting kit-8 (CCK8) assay, and the following table presents the results. No cytotoxicity was observed at the highest concentration tested by the CCK8 assay (1 mM).
Here, 5′-OH should have been triphosphorylated when derivatives 1 and 2 worked as a chain terminator in cells. This phosphorylation process was stepwise. First, 5′-OH was transformed by cellular phosphatase into generating 5′-O-monophosphate. Next, 5′-monophosthate was transformed into 5′-diphosphate and then into 5′-triphosphate. We assumed that the cellular phosphatase involved in the first step could slowly phosphorylate the 5′-OH of the derivatives because 5′-OH was sterically hindered by the 4′-ethynyl group. However, a 5′-O-monophosphate analog could be much more efficiently phosphorylated by cellular phosphatase to generate a 5′-diphosphate analog. We designed compounds 4 and 5 based on these assumptions (Figure 2) [27]. Compounds 4 and 5 equipped the cyclosaligenyl (cycloSal) group on phosphate ester, which increased the compound permeability [28,29,30]. This phosphate ester should have been cleaved by esterase in cells as a prodrug. We synthesized a 4′-ethynyl-2-fluoro-2′-deoxyadenosine 5′-monophosphate analog called EFdAP (4, Figure 2) (data not shown) and evaluated its anti-influenza activity. However, the activity (IC50 = 57 μM) was not improved when compared to EFdA. Therefore, we decided to synthesize and evaluate the activity of EdAP (5).

2.2. Synthesis of EdAP (5)

The synthesis of derivative 5 was initiated from diol 6 [31] (Scheme 1). The tert-butyldiphenylsilyl (TBDPS) protection of β-methylene alcohol in 6 generated alcohol 7 in a 67% yield. The (2,2,6,6-tetramethylpiperidin-1-yl)oxyl (TEMPO) oxidation of alcohol 7 and the subsequent treatment of the resulting aldehyde 8 with tetrabromomethane and triphenylphosphine generated dibromoolefine 9 in a 96% yield over two steps [32]. Dibromoolefine 9 was treated with n-BuLi, followed by chlorotriethylsilane(TESCl), to provide chlorotriethylsilane (TES)-protected alkyne 10 in an 83% yield. The treatment of the resulting acetal 10 with AcOH generated hemiacetal 11, which was acetylated with Ac2O to afford diacetate 12 as a diastereomeric mixture of the acetoxy group in an 84% yield. The one-pot Silyl–Hilbert–Johnson reaction between adenine and acetate 12 furnished the desired adenosine derivative 13 in a 73% yield [33,34]. After the deacetylation of 13, the resulting alcohol 14 was converted to phenylthiocarbonate 15 in a 63% yield, which was treated with Bu3SnH and azobisisobutyronitrile (AIBN) to generate deoxy adenosine derivative 16 in an 86% yield [35,36]. The deprotection of the TBDPS group in 16 and the introduction of phosphate ester by chlorophosphite 17 and H2O2 aq, followed by the deprotection of the p-Methoxybenzyl (PMB) group by cerium ammonium nitrate (CAN), afforded EdAP (5).

2.3. Anti-Influenza Activity of EdAP (5)

The in vitro anti-influenza activity of compound 5 was analyzed (Figure 3). Consequently, compound 5 significantly inhibited the growth of the influenza virus, with an IC50 of 3.8 μM, whereas no cytotoxicity was observed at the highest concentration tested by the CCK8 assay (1 mM). The maximum inhibition level of 5 was around a 79% decrease of influenza virus-produced NPs. This level is comparable to that of oseltamivir. Considering the result that the anti-influenza activity of the parent compound 2 was weak, phosphate ester 5 presumably worked as a prodrug. The introduced phosphate ester could be cleaved in cells to generate phosphate monoester. EdA (2) was easily hydrolyzed by adenosine deaminase to generate the corresponding inactive inosine derivative [6,11,37]. However, EdAP, which has the same scaffold as EdA, except in the case of cyclosaligenyl phosphate ester, exhibited anti-influenza activity. Thus, the cycloSal phosphate group could prevent the conversion of EdAP by adenosine deaminase, or other unknown mechanisms may exist.

3. Materials and Methods

3.1. Chemistry

Unless otherwise indicated, all the reactions were performed in oven-dried glassware fitted with a 3-way glass stopcock under an argon atmosphere and stirred with Teflon-coated magnetic stir bars. All work-up and purification procedures were performed with reagent-grade solvents under an ambient atmosphere. CH2Cl2 was distilled from P2O5 immediately before use. Et2O and tetrahydrofuran (THF) were distilled from sodium/benzophenone immediately before use. Et3N and N,N-diisopropylethylamine (DIEPA) were distilled from CaH2 and stored over KOH. CH3CN and toluene were distilled from CaH2 and stored over molecular sieves 4A. Chemical regents were of commercial grade and were used without any purification unless otherwise noted. Flash chromatography was performed on a PSQ-100B (Fuji Silysia Co., Ltd., Aichi, Japan) unless otherwise noted. Analysis thin layer chromatography (TLC) was performed using commercial silica gel plates (TLC Silica Gel 60 F254, Merck Millipore, Massachusetts, United States). Infrared spectra (IR) were recorded on a Jasco FT/IR-410 spectrometer using NaCl (neat). High-resolution mass spectra (HRMS) were obtained from an Applied Biosystems mass spectrometer (APIQSTAR pulsar I) for electrospray ionization (ESI). Polyethylene glycol was used as the internal standard. HRMS data are reported as m/z (relative intensity), with an accurate mass reported for the molecular ion [M + Na]+. 1H and 13C-NMR spectra were recorded on a Bruker 600 MHz spectrometer (Avance DRX-600) with CDCl3 or MeOD as a solvent. Tetramethylsilane (TMS) was used as an internal standard (δ 0.0) for 1H-NMR. Chemical shifts for 13C-NMR were reported in ppm relative to the center line of a triplet at 77.0 ppm in CDCl3 or a septet at 49.0 ppm in MeOD as a solvent. Multiplicities are indicated as br (broad), s (singlet), d (doublet), t (triplet), q (quartet), or m (multiplet). Coupling constants (J) are reported in hertz (Hz). The diastereomeric ratio was determined by 1H-NMR analysis. Optical rotations were determined using a JASCO P-1010 digital polarimeter in 100-mm cells and with a sodium D line (589 nm) at room temperature in the solvent and concentration indicated.

3.1.1. Synthesis of ((3aR,5R,6S,6aR)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-6-((4-methoxybenzyl)oxy)-2,2-dimethyltetrahydrofuro [2,3-d][1,3]dioxol-5-yl)methanol (7)

To a stirred solution of diol 6 (10.3 g, 30 mmol) in CH2Cl2 (40 mL) and Et3N (20 mL) was added tert-butylchlorodiphenylsilane (7.1 mL, 27 mmol). After stirring for 16 h, saturated aqueous NaCO3 solution was added to the mixture. The resulting reaction mixture was extracted with EtOAc, and the combined organic layer was washed with H2O, dried over brine and Na2SO4, and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography to afford alcohol 7 (10.9 g, 63%) as a white crystal. 7: Colorless crystal; Rf 0.8 (hexane/EtOAc = 1/1); [α]D20 + 38.1 (c 1.15, CHCl3); 1H-NMR (600 MHz, CDCl3), δ in ppm 7.63–7.59 (m, 4H), 7.44–7.40 (m, 2H), 7.38–7.35 (m, 4H), 7.28 (d, J = 8.6 Hz, 2H), 6.86 (d, J = 8.6 Hz, 2H), 5.81 (d, J = 3.8 Hz, 1H), 4.75 (d, J = 11.6 Hz, 1H), 4.67 (dd, J = 5.2, 3.8 Hz, 1H), 4.45 (d, J = 11.6 Hz, 1H), 4.42 (d, J = 5.2 Hz, 1H), 3.81 (dd, J = 11.9, 6.4 Hz, 1H), 3.79 (dd, J = 11.9, 7.2 Hz, 1H), 3.79 (s, 3H), 3.75 (d, J = 11.1 Hz, 1H), 3.66 (d, J = 11.1 Hz, 1H), 2.41 (dd, J = 7.2, 6.4 Hz, 1H), 1.65 (s, 3H), 1.37 (s, 3H), 0.99 (s, 9H); 13C-NMR (150 MHz, CDCl3) δC 159.5, 135.60 (2C), 135.55 (2C), 133.2, 133.0, 129.74, 129.67, 129.5 (2C), 129.3, 127.71 (2C), 127.68 (2C), 114.0 (2C), 113.7, 104.5, 87.4, 79.2, 77.5, 72.2, 65.4, 63.3, 55.2, 26.9, 26.8 (3C), 26.3, 19.2; IR νmax (film) 3545, 2939, 2862, 1612, 1514, 1464, 1429, 1379, 1250, 1215, 1107, 1028 cm−1; HRMS (ESI) m/z = calcd 601.2592 [M + Na]+, found 601.2600 [M + Na]+; mp 113 °C (see Supplementary Materials).

3.1.2. Synthesis of tert-butyl(((3aR,5R,6S,6aR)-5-(2,2-dibromovinyl)-6-((4-methoxybenzyl)oxy)-2,2- dimethyltetrahydrofuro[2,3-d][1,3]dioxol-5-yl)methoxy)diphenylsilane (9)

To a stirred solution of 7 (17.4 g, 30 mmol) in CH2Cl2 (60 mL) and NaHCO3 (60 mL, 0.25 M in H2O) were added TEMPO (47 mg, 0.3 mmol) and KBr (360 mg, 3.0 mmol). After the slow addition of NaOCl (24 mL, 12% in H2O) at 0 °C, the resulting mixture was stirred for 30 min. The resulting reaction mixture was extracted with EtOAc, and the combined organic layer was washed with H2O, dried over brine and Na2SO4, and concentrated under reduced pressure to give crude aldehyde 8, which was directly used in the next step without further purification. To a stirred solution of the above aldehyde 8 in CH2Cl2 (100 mL) and Et3N (16.7 mL, 120 mmol) were added CBr4 (20 g, 60 mmol) and PPh3 (31.5 g, 120 mmol) at 0 °C. After stirring for 18 h at room temperature (rt), the reaction was quenched with H2O. After filtration of the resulting reaction mixture through a pad of celite, the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography to afford dibromoolefine 9 (21 g, 96%) as a colorless oil. 9: Pale yellow oil; Rf 0.6 (hexane/EtOAc = 4/1); [α]D19 −40.1 (c 1.02, CHCl3); 1H-NMR (600 MHz, CDCl3), δ in ppm 7.66–7.61 (m, 4H), 7.44–7.30 (m, 8H), 7.08 (s, 1H), 6.86 (d, J = 8.6 Hz, 2H), 5.73 (d, J = 4.0 Hz, 1H), 4.75 (d, J = 11.9 Hz, 1H), 4.62 (d, J = 11.9 Hz, 1H), 4.55 (dd, J = 4.3, 4.0, 1H), 4.35 (d, J = 4.3 Hz, 1H), 3.99 (d, J = 11.6 Hz, 1H), 3.77 (s, 3H), 3.54 (d, J = 11.6, 1H), 1.58 (s, 3H), 1.32 (s, 3H), 0.98 (s, 9H); 13C-NMR (150 MHz, CDCl3) δC 170.9, 159.5, 135.9 (2C), 135.5 (2C), 135.3, 133.5, 132.6, 129.7 (2C), 129.6 (2C), 129.4, 127.7 (2C), 127.6 (2C), 114.0 (2C), 113.1, 103.8, 90.5, 85.6, 76.1, 72.2, 61.6, 55.2, 26.8 (3C), 26.0, 25.8, 19.3; IR νmax (film) 3047, 2862, 1608, 1514, 1252, 1107, 1024 cm−1; HRMS (ESI) m/z = calcd 753.0853 [M + Na]+, found 753.0877 [M + Na]+.

3.1.3. Synthesis of tert-butyl(((3aR,5R,6S,6aR)-6-((4-methoxybenzyl)oxy)-2,2-dimethyl-5-((triethylsilyl) ethynyl)tetrahydrofuro[2,3-d][1,3]dioxol-5-yl)methoxy)diphenylsilane (10)

To a stirred solution of dibromoalkene 9 (21 g, 29 mmol) in THF (300 mL) was added n-BuLi (20.9 mL, 2.76 M in hexane) at −78 °C. After stirring for 2 h at −30 °C, n-BuLi (4.2 mL, 2.76 M in hexane) was added. After stirring for 1 h at −30 °C, chlorotriethylsilane (5 mL, 30 mmol) was added at −78 °C. After stirring for 2 h at −78 °C, the reaction was quenched with H2O at 0 °C. The resulting mixture was extracted with EtOAc, and the combined organic layer was washed with H2O, dried over brine and Na2SO4, and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography to afford acetonide 10 (16.5 g, 83%) as a colorless oil. 10: Pale yellow oil; Rf 0.7 (hexane/EtOAc = 4/1); [α]D22 -49.0 (c 0.52, CHCl3); 1H-NMR (600 MHz, CDCl3), δ in ppm 7.63–7.60 (m, 4H), 7.44–7.35 (m, 6H), 7.31 (d, J = 8.6 Hz, 2H), 6.83 (d, J = 8.6 Hz, 2H), 5.73 (d, J = 3.5 Hz, 1H), 4.70–4.64 (m, 3H), 4.41 (d, J = 4.7 Hz, 1H), 3.91 (d, J = 11.3 Hz, 1H), 3.78 (s, 3H), 3.70 (d, J = 11.3 Hz, 1H), 1.74 (s, 3H), 1.36 (s, 3H), 0.97 (s, 9H), 0.93 (t, J = 7.9 Hz, 9H), 0.56 (q, J = 7.9 Hz, 6H); 13C-NMR (150 MHz, CDCl3) δC 159.2, 135.7 (2C), 135.5 (2C), 133.3, 132.7, 130.0, 129.73, 129.69, 129.2 (2C), 127.71 (2C), 127.70 (2C), 114.1, 113.7 (2C), 103.9, 103.4, 90.9, 81.9, 79.5, 76.4, 71.9, 67.3, 55.2, 26.8 (3C), 26.5, 26.4, 19.3, 7.4 (3C), 4.1 (3C); IR νmax (film) 2952, 2166, 1514, 1462, 1167 cm-1; HRMS (ESI) m/z = calcd 709.3351 [M + Na]+, found 709.3358 [M + Na]+.

3.1.4. Synthesis of (3R,4S,5R)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-4-((4-methoxybenzyl)oxy)-5- ((triethylsilyl)ethynyl)tetrahydrofuran-2,3-diyl diacetate (12)

A solution of acetonide 10 (16.5 g, 24 mmol) in AcOH (240 mL) and H2O (60 mL) was stirred for 5 h at 65 °C. Concentration of the reaction mixture with toluene gave crude hemiacetal 11, which was directly used in the next step without further purification. A solution of the above crude hemiacetal 11 in pyridine (60 mL) and Ac2O (20 mL) was stirred for 10 h at rt. After concentration of the reaction mixture with toluene, the resulting residue was purified by silica gel column chromatography to afford acetal 12 (14.5 g, 83%) as a colorless oil. 12: Pale yellow oil; Rf 0.5 (hexane/EtOAc = 4/1); 1H-NMR (600 MHz, CHCl3), δ in ppm 7.67–7.62 (m, 4H), 7.44–7.40 (m, 2H), 7.38–7.35 (m, 4H), 7.24 (d, J = 8.6 Hz, 2H), 6.84 (d, J = 8.6 Hz, 2H), 6.28 (s, 1H), 5.36 (d, J = 4.9 Hz, 1H), 4.60–4.55 (3H, overlapped), 3.85 (d, J = 11.1 Hz, 1H), 3.79 (s, 3H), 3.77 (d, J = 11.1 Hz, 1H), 2.09 (s, 3H), 1.80 (s, 3H), 1.05 (s, 9H), 0.92 (t, J = 7.9 Hz, 9H), 0.55 (q, J = 7.9 Hz, 6H); HRMS (ESI) m/z = calcd 753.3249 [M + Na]+, found 753.3259 [M + Na]+.

3.1.5. Synthesis of (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-4- ((4-methoxybenzyl)oxy)-5-((triethylsilyl)ethynyl)tetrahydrofuran-3-yl acetate (13)

To a stirred solution of acetal 12 (5.7 g, 7.8 mmol) in 1,2-dichloroethane (15 mL) were added adenine (3.2 g, 24 mmol) and N,O-bis(trimethylsilyl)acetamide (11.5 mL, 47 mmol). After stirring for 5 h under reflux conditions, trimethylsilyl trifluoromethanesulfonate (TMSOTf) (4.2 mL, 23 mmol) was added at 0 °C. After stirring for 10 h under reflux conditions, a saturated NaHCO3 solution was added to the mixture at rt. After filtration of the resulting mixture through a pad of celite, the filtrate was extracted with EtOAc, and the combined organic layer was washed with H2O, dried over brine and Na2SO4, and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography to afford nucleoside 13 (4.6 g, 73%) as a colorless oil. 13: Colorless oil; Rf 0.3 (Hexane/EtOAc = 1/2); [α]D20 -31.3 (c 0.61, CHCl3); 1H-NMR (600 MHz, CDCl3), δ in ppm 8.19 (s, 1H), 7.91 (s, 1H), 7.65–7.62 (m, 4H), 7.45–7.36 (m, 2H), 7.34–7.32 (m, 4H), 7.27 (d, J = 8.5 Hz, 2H), 6.85 (d, J = 8.5 Hz, 2H), 6.28 (d, J = 5.0 Hz, 1H), 5.93 (1H, dd, J = 6.1, 5.0 Hz, 1H), 5.47 (brs, 2H), 4.82 (d, J = 6.1 Hz, 1H), 4.73 (d, J = 11.1 Hz, 1H), 4.54 (d, J = 11.1 Hz, 1H), 4.03 (d, J = 11.2 Hz, 1H), 3.81 (d, J = 11.2 Hz, 1H), 3.80 (s, 3H), 2.02 (s, 3H), 1.03 (s, 9H), 0.96 (t, J = 7.9 Hz, 9H), 0.59 (q, J = 7.9 Hz, 6H); 13C-NMR (150 MHz, CDCl3) δC 170.0, 159.2, 155.3, 153.2, 149.8, 139.7, 135.6 (2C), 135.5 (2C), 132.64, 132.56, 129.89, 129.86, 129.82, 129.3 (2C), 127.7 (4C), 120.1, 113.6 (2C), 102.0, 91.6, 86.5, 83.5, 76.5, 73.6, 73.3, 66.7, 55.3, 26.8 (3C), 20.6, 19.2, 7.4 (3C), 4.2 (3C); IR νmax (film) 3319, 3167, 2170, 1745, 1599, 1469 cm−1; HRMS (ESI) m/z = calcd 828.3583 [M + Na]+, found 828.3559 [M + Na]+.

3.1.6. Synthesis of (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-4-((4- methoxybenzyl)oxy)-5-((triethylsilyl)ethynyl)tetrahydrofuran-3-ol (14)

A solution of nucleoside 13 (4.6 g, 5.7 mmol) in MeOH (60 mL) and Et3N (15 mL) was stirred for 18 h at rt. After concentration of the reaction mixture, the resulting residue was purified by silica gel column chromatography to afford alcohol 14 (3.5 g, 80%) as a colorless oil. 14: Colorless oil; Rf 0.5 (EtOAc); [α]D21 −19.8 (c 0.66, CDCl3); 1H-NMR (600 MHz, CHCl3), δ in ppm 8.20 (s, 1H), 7.90 (s, 1H), 7.62–7.60 (m, 4H), 7.43–7.40 (m, 2H), 7.34–7.32 (m, 6H), 6.88 (d, J = 8.6 Hz, 2H), 6.07 (d, J = 5.1 Hz, 1H), 5.48 (br s, 2H), 4.91 (d, J = 11.2 Hz, 1H), 4.87 (ddd, J = 7.9, 6.1, 5.1 Hz, 1H), 4.67 (d, J = 11.2 Hz, 1H), 4.58 (d, J = 6.1 Hz, 1H), 3.99 (d, J = 11.0 Hz, 1H), 3.83 (d, J = 11.0 Hz, 1H), 3.81 (s, 3H), 3.56 (d, J = 7.9 Hz, 1H), 1.02 (s, 9H), 0.97 (t, J = 7.9 Hz, 9H), 0.62 (q, J = 7.9 Hz, 6H); 13C-NMR (150 MHz, CDCl3) δC 159.6, 155.3, 153.0, 149.7, 139.8, 135.6 (2C), 135.5 (2C), 132.6, 132.5, 129.92, 129.89, 129.7 (2C), 129.2, 127.78 (2C), 127.76 (2C), 120.2, 113.9 (2C), 102.5, 92.1, 89.9, 83.3, 77.3, 73.2, 73.0, 66.9, 55.3, 26.8 (3C), 19.2, 7.4 (3C), 4.2 (3C); IR νmax (film) 3327, 3172, 2170, 1645, 1471, 1109 cm−1; HRMS (ESI) m/z = calcd 786.3482 [M + Na]+, found 786.3499 [M + Na]+.

3.1.7. Synthesis of O-((2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-4- ((4-methoxybenzyl)oxy)-5-((triethylsilyl)ethynyl)tetrahydrofuran-3-yl) O-phenyl carbonothioate (15)

To a stirred solution of alcohol 14 (3.5 g, 4.6 mmol) in MeCN (30 mL) were added N,N-dimethyl-4-aminopyridine (DMAP) (1.1 g, 9.2 mmol) and O-phenyl carbonochloridothioate (635 μL, 4.6 mmol) at 0 °C. After stirring for 21 h, the reaction mixture was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography to afford thiocarbonate 15 (2.6 g, 63%) as a colorless oil. 15: Colorless oil; Rf 0.6 (hexane/EtOAc = 1/2); [α]D21 −63.8 (c 0.52, CHCl3); 1H-NMR (600 MHz, CDCl3), δ in ppm 8.15 (s, 1H), 7.91 (s, 1H), 7.67–7.63 (m, 4H), 7.43-7.39 (m, 2H), 7.37–7.28 (m, 9H), 6.91 (d, J = 8.3 Hz, 2H), 6.87 (d, J = 8.7 Hz, 2H), 6.47 (dd, J = 5.9, 5.3 Hz, 1H), 6.41 (d, J = 5.3 Hz, 1H), 5.49 (brs, 2H), 5.11 (d, J = 5.9 Hz, 1H), 4.87 (d, J = 11.0 Hz, 1H), 4.64 (d, J = 11.0 Hz, 1H), 4.11 (d, J = 11.2 Hz, 1H), 3.86 (d, J = 11.2 Hz, 1H), 3.81 (s, 3H), 1.03 (s, 9H), 0.97 (t, J = 7.9 Hz, 9H), 0.61 (q, J = 7.9 Hz, 6H); 13C-NMR (150 MHz, CDCl3) δC 194.3, 159.3, 155.3, 153.4, 153.3, 149.9, 140.1, 135.64 (2C), 135.61 (2C), 132.6 (2C), 129.9, 129.81, 129.80, 129.6 (2C), 129.5 (2C), 127.75 (2C), 127.73 (2C), 126.6, 121.7 (2C), 120.2, 113.7 (2C), 101.8, 92.2, 86.2, 83.6, 80.6, 76.2, 73.8, 66.6, 55.3, 26.8 (3C), 19.2, 7.4 (3C), 4.2 (3C); IR νmax (film) 3315, 2956, 2171, 1643, 1105, 1009 cm−1; HRMS (ESI) m/z = calcd 922.3460 [M + Na]+, found 922.3451 [M + Na]+.

3.1.8. Synthesis of 9-((2R,4S,5R)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-4-((4-methoxybenzyl)oxy)-5-((triethylsilyl)ethynyl)tetrahydrofuran-2-yl)-9H-purin-6-amine (17)

To a stirred solution of thiocarbonate 15 (2.6 g, 2.9 mmol) in toluene (60 mL) were added HSnBu3 (4.6 mL, 17 mmol) and AIBN (117 mg, 0.7 mmol). After stirring for 30 min at 130 °C, the reaction mixture was concentrated under reduced pressure. The resulting residue was roughly purified by silica gel column chromatography to afford nucleoside 16 as a colorless oil. To a stirred solution of nucleoside 16 above in THF (20 mL) was added tetra-n-butylammonium fluoride (TBAF) (4.8 mL, 1 M in THF) at rt. After stirring for 2 h, the reaction mixture was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography to afford alcohol 17 (982 mg, 86%) as a colorless oil. 17: Pale yellow crystal; Rf 0.5 (EtOAc); [α]D21 + 6.41 (c 0.56, CHCl3); 1H-NMR (600 MHz, CDCl3), δ in ppm 8.30 (s, 1H), 7.77 (s, 1H), 7.35 (d, J = 8.4 Hz, 2H), 6.90 (d, J = 8.4 Hz, 2H), 6.80 (br d, J = 12.3 Hz, 1H), 6.36 (dd, J = 9.2, 5.7 Hz, 1H), 5.76 (brs, 2H), 4.82 (d, J = 11.3 Hz, 1H), 4.60 (d, J = 11.3 Hz, 1H), 4.52 (d, J = 5.8 Hz, 1H), 4.06 (d, J = 12.5 Hz, 1H), 3.84 (dd, J = 12.5, 12.3 Hz, 1H), 3.82 (s, 3H), 3.09 (ddd, J = 13.5, 9.2, 5.8 Hz, 1H), 2.72 (s, 1H), 2.44 (dd, J = 13.5, 5.7 Hz, 1H); 13C-NMR (150 MHz, CDCl3) δC 159.4, 155.9, 152.4, 148.5, 140.2, 129.6, 129.4 (2C), 121.2, 113.9 (2C), 87.2, 86.7, 80.3, 79.7, 77.0, 72.5, 68.6, 55.3, 38.8; IR νmax (film) 3298, 2949, 2400, 1682, 1514, 1425 cm−1; HRMS (ESI) m/z = calcd 418.1485 [M + Na]+, found 418.1488 [M + Na]+.

3.1.9. Synthesis of 2-(((2R,3S,5R)-5-(6-amino-9H-purin-9-yl)-2-ethynyl-3-((4-methoxybenzyl)oxy) tetrahydrofuran-2-yl)methoxy)-4H-benzo[d][1,3,2]dioxaphosphinine 2-oxide (18)

To a stirred solution of alcohol 17 (200 mg, 0.51 mmol) in MeCN (5 mL) were added DIPEA (178 μL, 1.0 mmol) and 2-chloro-4H-benzo[d][1,3,2]dioxaphosphinine (192 mg, 0.51 mmol) at 0 °C. After stirring for 1 h at 0 °C, H2O2 (250 μL, 30% in H2O) was added at 0 °C. After stirring for 1 h at 0 °C, the resulting mixture was directly purified by silica gel column chromatography to afford phosphoester 18 (220 mg, 76%) as a colorless oil. 18: Pale yellow oil; Rf 0.7 (CHCl3/MeOH = 8/1); [α]D21 −7.85 (c 0.53, CHCl3); 1H-NMR (600 MHz, CDCl3), δ in ppm major-isomer 8.19 (s, 1H), 7.78 (s, 1H), 7.32–7.24 (4H, overlapped), 7.12–7.09 (m, 1H), 6.99–6.94 (2H, overlapped), 6.90–6.86 (2H, overlapped), 6.34–6.31 (1H, overlapped), 5.60 (2H, brs), 5.26–5.14 (2H, overlapped), 4.72–4.67 (2H, overlapped), 4.58 (d, J = 11.6 Hz, 1H), 4.52–4.49 (m, 1H), 4.37–4.34 (m, 1H), 3.80 (s, 3H), 2.89–2.85 (1H, overlapped), 2.67 (s, 1H), 2.66–2.61 (1H, overlapped); minor-isomer 8.26 (s, 1H), 7.80 (s, 1H), 7.32–7.24 (4H, overlapped), 7.09–7.06 (m, 1H), 6.99–6.94 (2H, overlapped), 6.90–6.86 (2H, overlapped), 6.34–6.31 (1H, overlapped), 5.62 (2H, brs), 5.26–5.14 (2H, overlapped), 4.72–4.67 (2H, overlapped), 4.62 (d, J = 11.6 Hz, 1H), 4.47–4.44 (m, 1H), 4.41–4.38 (m, 1H), 3.81 (s, 3H), 2.89–2.85 (1H, overlapped), 2.67 (s, 1H), 2.66–2.61 (1H, overlapped); IR νmax (film) 3175, 2114, 1643, 1597, 1513, 1458 cm−1; HRMS (ESI) m/z = calcd 586.1462 [M + Na]+, found 586.1467 [M + Na]+.

3.1.10. Synthesis of 2-(((2R,3S,5R)-5-(6-amino-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl) methoxy)-4H-benzo[d][1,3,2]dioxaphosphinine 2-oxide (5)

To a stirred solution of phosphoester 18 (156 mg, 0.28 mmol) in MeCN (2.5 mL) and H2O (0.5 mL) was added ceric ammonium nitrate (614 mg, 1.1 mmol) at 0 °C. After stirring for 20 min at 0 °C, the resulting mixture was directly purified by silica gel column chromatography to afford 5 (93 mg, 75%) as a white solid. 5: Colorless crystal; Rf 0.5 (EtOAc/MeOH = 10/1); 1H-NMR (600 MHz, MeOD), δ in ppm major-isomer 8.34 (s, 1H), 8.26 (s, 1H), 7.30–7.26 (1H, overlapped), 7.15–7.11 (1H, overlapped), 7.07–7.06 (m, 1H), 6.96–6.94 (m, 1H), 6.45–6.41 (1H, overlapped), 5.43–5.26 (2H, overlapped), 4.94–4.87 (1H, overlapped), 4.44–4.35 (2H, overlapped), 3.21 (s, 1H), 2.94–2.89 (1H, overlapped), 2.73–2.67 (1H, overlapped); minor-isomer 8.37 (s, 1H), 8.30 (s, 1H), 7.30–7.26 (1H, overlapped), 7.15–7.11 (2H, overlapped), 6.91 (d, J = 8.2 Hz, 1H), 6.45-6.41 (1H, overlapped), 5.43–5.26 (2H, overlapped), 4.94–4.87 (1H, overlapped), 4.44–4.35 (2H, overlapped), 3.19 (s, 1H), 2.94–2.89 (1H, overlapped), 2.73-2.67 (1H, overlapped); 13C-NMR (150 MHz, MeOD) δC major-isomer 152.2, 151.0 (d, JC-P = 6.5 Hz), 149.4, 145.9, 144.2, 131.0, 126.7, 125.81, 122.0, 120.7, 119.3 (d, JC-P = 8.8 Hz), 84.8, 84.41, 80.12, 78.7, 71.5, 70.0 (d, JC-P = 6.6 Hz), 38.42; Minor-isomer 152.3, 150.9 (d, JC-P = 7.6 Hz), 149.5, 146.0, 144.1, 130.9, 126.8, 125.79, 121.9, 120.6, 119.2 (d, JC-P = 7.7 Hz), 84.7, 84.36, 80.06, 78.8, 71.6, 70.2 (d, JC-P = 6.5 Hz), 38.37; IR νmax (film) 3246, 3070, 2115, 1688, 1609, 1489 cm−1; UV (MeOH) λmax (log ε) 212 (4.35), 261 (3.83) nm; HRMS (ESI) m/z = calcd 466.0886 [M + Na]+, found 466.0889 [M + Na]+.

3.2. Biological Assays

3.2.1. Cells

MDCK cells and MDCK–SIAT1 cells were cultivated in minimal essential medium (MEM), which was supplemented with 10% heat-inactivated fetal bovine serum from Tissue Culture Biological, Tulare, CA, and 1% penicillin-streptomycin solution from GIBCO-BRL, Rockville, MD.

3.2.2. Virus

As described previously [38], the number of influenza A/Narita/1/09 H1N1pdm viruses were increased in MDCK–SIAT1 cells containing 1% penicillin-streptomycin solution and 5 μg/mL acetylated trypsin at 37 °C in 5% CO2 atmosphere for 3 days. The viruses in the culture were harvested, pooled, and clarified before concentration and resuspension in cold phosphate-buffered saline. After aliquoting, aliquots were kept at −80 °C until use.

3.2.3. Cytotoxicity Assay

As described previously [39], each inhibitor was serially diluted in serum-free MEM and transferred onto confluent monolayers of MDCK–SIAT1. After incubation at 37 °C in a 5% CO2 atmosphere for 24 h, the viable cell number was determined with a cell counting kit-8 from DOJINDO Laboratories, Kumamoto, Japan.

3.2.4. Influenza Growth Inhibition Assay

After two washes with MEM, MDCK–SIAT1 cells were preincubated with an inhibitor at various concentrations in MEM at 37 °C in 5% CO2 atmosphere for 1 h. Influenza virus at a multiplicity of infection of 0.03 was pretreated with the same inhibitor at the same concentrations in MEM with 2 μg/mL acetylated trypsin at 4 °C for 1 h. The inhibitor-containing MEM medium on the cells was replaced with the influenza virus-inhibitor mixture. After incubation at 37 °C in a 5% CO2 atmosphere for 19–20 h, the medium was removed. Immediately, the infected cells were fixed and permeabilized with methanol. After two washes, the permeabilized cells were stained with primary antiviral NP mouse antibody (4E6) and secondary β-galactosidase-conjugated antimouse IgG antibody. The number of influenza virus-produced nucleoproteins (NPs) in the permeabilized cells in each well was determined by a galactosidase-based fluorescent assay, as previously described [26]. A percentage of the fluorescent intensity of each well relative to the fluorescent intensity of the no-inhibitor control well that contained only the virus was used to express the number of influenza virus-produced NPs in each well. Then, a graph was generated by plotting the percentage of relative numbers of influenza virus-produced NPs against the logarithm of the inhibitor concentrations. After fitting the points on the graph through Prism’s nonlinear regression analysis, the inhibitor concentration that inhibited virus multiplication by 50% in comparison to the control (IC50) was obtained. The influenza virus-produced NPs in the permeabilized cells in each well were visualized as a blue color by a peroxidase-based chromogenic assay [40].

4. Conclusions

Thus, we developed EdAP, a new 4′-ethynyl-2′-deoxyadenosine 5′-monophosphate analog, as a potent influenza A inhibitor with an IC50 of 3.8 μM. EdAP was designed based on the results of the anti-influenza activities of several 4′-ethynyl-adenosine derivatives. The obtained observations could provide helpful information for developing new anti-influenza nucleosides.

Supplementary Materials

The spectra of 1H of compounds 5, 7, and 9–18 and the 13C-NMR of compounds 5, 7, and 9–17 are available online.

Author Contributions

T.T., A.S., and E.H. performed the syntheses; N.S. analyzed anti-influenza activities and cytotoxicity; T.T. and S.K. conceived of and designed the synthetic experiments; Y.S., O.H., and F.S. supervised and evaluated the synthetic and biological studies. Writing—original draft, T.T.; writing—review and editing, N.S., S.K., Y.S., H.O., and F.S.

Funding

This research received no external funding.

Conflicts of Interest

There are no conflicts to declare.

References

  1. Global Influenza Strategy 2019–2030; World Health Organization: Geneva, Switzerland, 2019.
  2. Stevaert, A.; Naesens, L. The influenza virus polymerase complex: An update on its structure, functions, and significance for antiviral drug design. Med. Res. Rev. 2016, 36, 1127–1173. [Google Scholar] [CrossRef] [PubMed]
  3. Laborda, P.; Wang, S.-Y.; Voglmeir, J. Influenza Neuraminidase Inhibitors: Synthetic Approaches, Derivatives and Biological Activity. Molecules 2016, 21, 1513. [Google Scholar] [CrossRef] [PubMed]
  4. Das, K. Antivirals Targeting Influenza A Virus. J. Med. Chem. 2012, 14, 6263–6277. [Google Scholar] [CrossRef] [PubMed]
  5. Kohgo, S.; Ohrui, H.; Kodama, E.; Matsuoka, M.; Mitsuya, H. 4′-c-Substituted-2-Haloadenosine Derivative. U.S. Patent 2502199, 4 March 2005. [Google Scholar]
  6. Kohgo, S.; Yamada, K.; Kitano, K.; Iwai, Y.; Sakata, S.; Ashida, N.; Hayakawa, H.; Nameki, D.; Kodama, E.; Matsupka, M.; et al. Design, efficient synthesis, and anti-HIV activity of 4′-C-cyano- and 4′-C-ethynyl-2′-deoxy purine nucleosides. Nucleosides Nucleotides Nucleic Acids 2004, 23, 671–690. [Google Scholar] [CrossRef] [PubMed]
  7. Ohrui, H. 2′-deoxy-4′-C-ethynyl-2-fluoroadenosine, a nucleoside reverse transcriptase inhibitor, is highly potent against all human immunodeficiency viruses type 1 and has low toxicity. Chem. Rec. 2006, 6, 133–143. [Google Scholar] [CrossRef] [PubMed]
  8. Ohrui, H.; Hayakawa, H.; Kohgo, S.; Matsuoka, M.; Kodama, E.; Mitsuya, H. Creation of Low Toxic Reverse-transcriptase Inhibitory Nucleosides that Prevent the Emergence of Drug-resistant HIV Variants. J. Synth. Org. Chem. Jpn. 2006, 64, 716–723. [Google Scholar] [CrossRef]
  9. Ohrui, H.; Kohgo, S.; Hayakawa, H.; Kodama, E.; Matsuoka, M.; Nakata, T.; Mitsuya, H. 2′-deoxy-4′-C-ethynyl-2-fluoroadenosine: A nucleoside reverse transcriptase inhibitor with highly potent activity against wide spectrum of HIV-1 strains, favorable toxic profiles, and stability in plasma. Nucleosides Nucleotides Nucleic Acids 2007, 26, 1543–1546. [Google Scholar] [CrossRef] [PubMed]
  10. Michailidis, E.; Marchand, B.; Kodama, E.; Singh, K.; Matsuoka, M.; Kirby, K.A.; Ryan, E.M.; Sawani, A.M.; Nagy, E.; Ashida, N.; et al. Mechanism of inhibition of HIV-1 reverse transcriptase by 4′-Ethynyl-2-fluoro-2′-deoxyadenosine triphosphate, a translocation-defective reverse transcriptase inhibitor. J. Biol. Chem. 2009, 284, 35681–35691. [Google Scholar] [CrossRef] [PubMed]
  11. Ohrui, H. Development of modified nucleosides that have supremely high anti-HIV activity and low toxicity and prevent the emergence of resistant HIV mutants. Proc. Jpn. Acad. Ser. B 2011, 87, 53–65. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  12. Michailidis, E.; Huber, A.D.; Ryan, E.M.; Ong, Y.T.; Leslie, M.D.; Matzek, K.B.; Singh, K.; Marchand, B.; Hagedorn, A.N.; Kirby, K.A.; et al. 4′-Ethynyl-2-fluoro-2′-deoxyadenosine (EFdA) inhibits HIV-1 reverse transcriptase with multiple mechanisms. J. Biol. Chem. 2014, 289, 24533–24548. [Google Scholar] [CrossRef] [PubMed]
  13. Kodama, E.; Kohgo, S.; Kitano, K.; Machida, H.; Gatanaga, H.; Shigeta, S.; Matsuoka, M.; Ohrui, H.; Mitsuya, H. 4′-Ethynyl nucleoside analogs: Potent inhibitors of multidrug-resistant human immunodeficiency virus variants in vitro. Antimicrob. Agents Chemother. 2001, 45, 1539–1546. [Google Scholar] [CrossRef] [PubMed]
  14. Kawamoto, A.; Kodama, E.; Sarafianos, S.G.; Sakagami, Y.; Kohgo, S.; Kitano, K.; Ashida, N.; Iwai, Y.; Hayakawa, H.; Nakata, H.; et al. 2008. 2′-Deoxy-4′-C-ethynyl-2-halo-adenosines active against drug-resistant human immunodeficiency virus type 1 variants. Int. J. Biochem. Cell Biol. 2008, 40, 2410–2420. [Google Scholar] [CrossRef] [PubMed]
  15. Michailidis, E.; Ryan, E.M.; Hachiya, A.; Kirby, K.A.; Marchand, B.; Leslie, M.D.; Huber, A.D.; Ong, Y.T.; Jackson, J.C.; Singh, K.; et al. Hypersusceptibility mechanism of Tenofovir-resistant HIV to EFdA. Retrovirology 2013, 10, 65. [Google Scholar] [CrossRef] [PubMed]
  16. Maeada, K.; Desai, D.V.; Aoki, M.; Nakata, H.; Kodama, E.N.; Mitsuya, H. Delayed emergence of HIV-1 variants resistant to 4′-ethynyl-2-fluoro-2′-deoxyadenosine: Comparative sequential passage study with lamivudine, tenofovir, emtricitabine and BMS-986001. Antivir. Ther. 2014, 19, 179–189. [Google Scholar] [CrossRef] [PubMed]
  17. Wu, V.H.; Smith, R.A.; Masoum, S.; Raugi, D.N.; Ba, S.; Seydi, M.; Grobler, J.A.; Gottlieb, G.S. MK-8591 (4′-ethynyl-2-fluoro-2′-deoxyadenosine) exhibits potent activity against HIV-2 isolates and drug-resistant HIV-2 mutants in culture. Antimicrob. Agents Chemother. 2017, 61, e00744-17. [Google Scholar] [CrossRef]
  18. Njenda, D.T.; Aralaguppe, S.G.; Singh, K.; Rao, R.; Sönnerborg, A.; Sarafianos, S.G.; Neogi, U. Antiretroviral potency of 4′-ethnyl-2′-fluoro-2′-deoxyadenosine, tenofovir alafenamide and second-generation NNRTIs across diverse HIV-1 subtypes. J. Antimicrob. Chemother. 2018, 73, 2721–2728. [Google Scholar] [CrossRef] [PubMed]
  19. Takamatsu, Y.; Das, D.; Kohgo, S.; Hayashi, H.; Delino, N.S.; Sarafianos, S.G.; Mitsuya, H.; Maeda, K. The High Genetic Barrier of EFdA/MK-8591 Stems from Strong Interactions with the Active Site of Drug-Resistant HIV-1 Reverse Transcriptase. Cell Chem. Biol. 2018, 25, 1268–1278. [Google Scholar]
  20. Murphey-Corb, M.; Rajakumar, P.; Michael, H.; Nyaundi, J.; Didier, P.J.; Reeve, A.B.; Mitsuya, H.; Sarafianos, S.G.; Parniak, M.A. Response of simian immunodeficiency virus to the novel nucleoside reverse transcriptase inhibitor 4′-ethynyl-2-fluoro-2′-deoxyadenosine in vitro and in vivo. Antimicrob. Agents Chemother. 2012, 56, 4707–4712. [Google Scholar] [CrossRef]
  21. Hachiya, A.; Reeve, A.B.; Marchand, B.; Michailidis, E.; Ong, Y.T.; Kirby, K.A.; Leslie, M.D.; Oka, S.; Kodama, E.N.; Rohan, L.C.; et al. Evaluation of combinations of 4′-ethynyl-2-fluoro-2′-deoxyadenosine with clinically used antiretroviral drugs. Antimicrob. Agents Chemother. 2013, 57, 4554–4558. [Google Scholar] [CrossRef]
  22. Zhang, W.; Parniak, M.A.; Mitsuya, H.; Sarafianos, S.G.; Graebing, P.W.; Rohan, L.C. Preformulation studies of EFdA, a novel nucleoside reverse transcriptase inhibitor for HIV prevention. Drug Dev. Ind. Pharm. 2014, 40, 1101–1111. [Google Scholar] [CrossRef]
  23. Stoddart, C.A.; Galkina, S.A.; Joshi, P.; Kosikova, G.; Moreno, M.E.; Rivera, J.M.; Sloan, B.; Reeve, A.B.; Sarafianos, S.G.; Murphey-Corb, M.; et al. Oral administration of the nucleoside EFdA (4′-ethynyl-2-fluoro-2′-deoxyadenosine) provides rapid suppression of HIV viremia in humanized mice and favorable pharmacokinetic properties in mice and the rhesus macaque. Antimicrob. Agents Chemother. 2015, 59, 4190–4198. [Google Scholar] [CrossRef]
  24. Markowitz, M.; Sarafianos, S.G. 4′-Ethynyl-2-fluoro-2′-deoxyadenosine, MK-8591: A novel HIV-1 reverse transcriptase translocation inhibitor. Curr. Opin. HIV AIDS 2018, 13, 294–299. [Google Scholar] [CrossRef] [PubMed]
  25. Ohrui, H.; Kohgo, S.; Kitano, K.; Sakata, S.; Kodama, E.; Yoshimura, K.; Matsuoka, M.; Shigeta, S.; Mitsuya, H. Syntheses of 4′-C-ethynyl-beta-D-arabino- and 4′-C-ethynyl-2′-deoxy-beta-D-ribo- pentofuranosylpyrimidines and -purines and evaluation of their anti-HIV activity. J. Med. Chem. 2000, 43, 4516–4525. [Google Scholar] [CrossRef] [PubMed]
  26. Sriwilaijaroen, N.; Wilairat, P.; Hiramatsu, H.; Takahashi, T.; Suzuki, T.; Ito, M.; Ito, Y.; Tashiro, M.; Suzuki, Y. Mechanisms of the action of povidone-iodine against human and avian influenza A viruses: Its effects on hemagglutination and sialidase activities. Virol. J. 2009, 6, 124. [Google Scholar] [CrossRef] [PubMed]
  27. Sugawara, F.; Takeuchi, T.; Kamisuki, S.; Ohrui, H.; Suzuki, Y. Japanese Kokai Tokkyo Koho. JP Patent 2015,151,346 A, 12 February 2015. [Google Scholar]
  28. Meier, C. 2-Nucleos-5′-O-yl-4H-1,3,2-benzodioxaphos-phinin-2-oxides—A new concept for lipophilic, potential prodrugs of biologically active nucleoside monophosphates. Angew. Chem. Int. Ed. Engl. 1996, 35, 70–72. [Google Scholar] [CrossRef]
  29. Meier, C.; Knispel, T.; Clercq, E.D.; Balzarini, J. cycloSal-Pronucleotides of 2′,3′-dideoxyadenosine and 2′, 3′-dideoxy-2′,3′-didehydroadenosine: Synthesis and antiviral evaluation of a highly efficient nucleotide delivery system. J. Med. Chem. 1999, 42, 1604–1614. [Google Scholar] [CrossRef] [PubMed]
  30. Meier, C.; Balzarini, J. Application of the cycloSal-prodrug approach for improving the biological potential of phosphorylated biomolecules. Antoviral Res. 2006, 71, 282–292. [Google Scholar] [CrossRef] [PubMed]
  31. Yamaguchi, R.; Imanishi, T.; Kohgo, S.; Horie, H.; Ohrui, H. Synthesis of 4′-C-ethynyl-β-D-ribo-pentofuranosyl pyrimidines. Biosci. Biotechnol. Biochem. 1999, 63, 736–742. [Google Scholar] [CrossRef] [PubMed]
  32. Corey, E.J.; Fuchs, P.L. A synthetic method for formyl→ethynyl conversion (RCHO→RC≡CH or RC≡CR′). Tetrahedron Lett. 1972, 36, 3769–3772. [Google Scholar] [CrossRef]
  33. Leonard, N.J.; Laursen, R.A. The synthesis of 3-β-d-ribofuranosyladenine. J. Am. Chem. Soc. 1963, 85, 2026–2028. [Google Scholar] [CrossRef]
  34. Leonard, N.J.; Laursen, R.A. Synthesis of 3-β-d-ribofuranosyladenine and (3-β-d-ribofuranosyladenine)-5′-phosphate. Biochemistry 1965, 4, 354–365. [Google Scholar] [CrossRef]
  35. Barton, D.H.R.; McCombie, S.W. A new method for the deoxygenation of secondary alcohols. J. Chem. Soc. Perkin. Trans. 1975, 1, 1574–1585. [Google Scholar] [CrossRef]
  36. Crich, D.; Quintero, L. Radical chemistry associated with the thiocarbonyl group. Chem. Rev. 1989, 89, 1413–1432. [Google Scholar] [CrossRef]
  37. Hayakawa, H.; Kohgo, S.; Kitano, K.; Ashida, N.; Kodama, E.; Mitsuya, H.; Ohrui, H. Potential of 4′-C-substituted nucleosides for the treatment of HIV-1. Antivir. Chem. Chemother. 2004, 15, 169–187. [Google Scholar] [CrossRef] [PubMed]
  38. Sriwilaijaroen, N.; Kadowaki, A.; Onishi, Y.; Gato, N.; Ujike, M.; Odagiri, T.; Tashiro, M.; Suzuki, Y. Mumefural and related HMF derivatives from Japanese apricot fruit juice concentrate show multiple inhibitory effects on pandemic influenza A (H1N1) virus. Food Chem. 2011, 127, 1–9. [Google Scholar] [CrossRef]
  39. Sriwilaijaroen, N.; Magesh, S.; Imamura, A.; Ando, H.; Ishida, H.; Sakai, M.; Ishitsubo, E.; Hori, T.; Moriya, S.; Ishikawa, T.; et al. A novel potent and highly specific inhibitor against influenza viral N1-N9 neuraminidases: Insight into neuraminidase-inhibitor interactions. J. Med. Chem. 2016, 59, 4563–4577. [Google Scholar] [CrossRef] [PubMed]
  40. Sriwilaijaroen, N.; Suzuki, K.; Takashita, E.; Hiramatsu, H.; Kanie, O.; Suzuki, Y. 6SLN-lipo PGA specifically catches (coats) human influenza virus and synergizes neuraminidase-targeting drugs for human influenza therapeutic potential. J. Antimicrob. Chemother. 2015, 70, 2797–2809. [Google Scholar] [CrossRef] [Green Version]
Sample Availability: Samples of the compounds are available from the authors.
Molecules 24 02603 g001 550
Figure 1. Structures of 4′-ethynyl-2-fluoro-2′-deoxyadenosine (EFdA) (1), 4′-ethynyl-2′-deoxyadenosine (EdA) (2), and 4′-ethynyl-2-fluoroadenosine (EA) (3).
Figure 1. Structures of 4′-ethynyl-2-fluoro-2′-deoxyadenosine (EFdA) (1), 4′-ethynyl-2′-deoxyadenosine (EdA) (2), and 4′-ethynyl-2-fluoroadenosine (EA) (3).
Molecules 24 02603 g001
Molecules 24 02603 g002 550
Figure 2. Structures of EFdAP (4) and EdAP (5).
Figure 2. Structures of EFdAP (4) and EdAP (5).
Molecules 24 02603 g002
Molecules 24 02603 sch001 550
Scheme 1. Synthesis of EdAP (5).
Scheme 1. Synthesis of EdAP (5).
Molecules 24 02603 sch001
Molecules 24 02603 g003 550
Figure 3. Inhibition of the influenza virus growth in the MDCK–SIAT1 cells by EdAP (5). Upper panel: The number of influenza virus-produced nucleoproteins (NPs) in cells decreased with an increase in EdAP concentration, as indicated. Lower panel: The reduction in the relative numbers of influenza virus-produced NPs in cells was a function of EdAP (filled circle and solid line) or oseltamivir carboxylate (open square and dashed line) concentrations, as indicated.
Figure 3. Inhibition of the influenza virus growth in the MDCK–SIAT1 cells by EdAP (5). Upper panel: The number of influenza virus-produced nucleoproteins (NPs) in cells decreased with an increase in EdAP concentration, as indicated. Lower panel: The reduction in the relative numbers of influenza virus-produced NPs in cells was a function of EdAP (filled circle and solid line) or oseltamivir carboxylate (open square and dashed line) concentrations, as indicated.
Molecules 24 02603 g003
Table
Table 1. The anti-influenza and cytotoxicity of compounds 1–3.
Table 1. The anti-influenza and cytotoxicity of compounds 1–3.
H1N1 Influenza A VirusMDCK–SIAT1
CompoundIC50 (μM)CC50 1 (μM)
163>1000
2401>1000
3>1000>1000
1 The cell counting kit-8 (CCK8) assay was used. IC50: 50% inhibitory concentration. CC50: 50% cytotoxic concentration. MDCK–SIAT1: Madin–Darby canine kidney cells transfected with human α2-6-sialyltransferase (SIAT1) cDNA.

Share and Cite

MDPI and ACS Style

Takeuchi, T.; Sriwilaijaroen, N.; Sakuraba, A.; Hayashi, E.; Kamisuki, S.; Suzuki, Y.; Ohrui, H.; Sugawara, F. Design, Synthesis, and Biological Evaluation of EdAP, a 4′-Ethynyl-2′-Deoxyadenosine 5′-Monophosphate Analog, as a Potent Influenza a Inhibitor. Molecules 2019, 24, 2603. https://doi.org/10.3390/molecules24142603

AMA Style

Takeuchi T, Sriwilaijaroen N, Sakuraba A, Hayashi E, Kamisuki S, Suzuki Y, Ohrui H, Sugawara F. Design, Synthesis, and Biological Evaluation of EdAP, a 4′-Ethynyl-2′-Deoxyadenosine 5′-Monophosphate Analog, as a Potent Influenza a Inhibitor. Molecules. 2019; 24(14):2603. https://doi.org/10.3390/molecules24142603

Chicago/Turabian Style

Takeuchi, Toshifumi, Nongluk Sriwilaijaroen, Ayako Sakuraba, Ei Hayashi, Shinji Kamisuki, Yasuo Suzuki, Hiroshi Ohrui, and Fumio Sugawara. 2019. "Design, Synthesis, and Biological Evaluation of EdAP, a 4′-Ethynyl-2′-Deoxyadenosine 5′-Monophosphate Analog, as a Potent Influenza a Inhibitor" Molecules 24, no. 14: 2603. https://doi.org/10.3390/molecules24142603

Article Metrics

Back to TopTop